Trump speeds review of psychedelics after Joe Rogan texted him about ibogaine. 'Let's do it'

Key Points:

• President Trump signed an executive order aimed at easing restrictions on ibogaine and other psychedelics to accelerate research and access for medical treatments, particularly for severe depression and conditions like PTSD and opioid addiction.
• The FDA plans to issue national priority review vouchers for three psychedelics, enabling faster drug approval processes, and is preparing to clear the way for the first human trials of ibogaine in the U.S.
• Despite ibogaine’s known risks of causing potentially fatal heart problems and its Schedule I classification, advocates including veterans, conservative figures, and former Texas Governor Rick Perry support its medical potential and increased research funding.
• The order includes a federal-state partnership directing at least $50 million to states with psychedelic programs, encouraging more states to fund research and potentially reducing stigma around Schedule I drugs.
• While ibogaine clinics currently operate mainly outside the U.S. and treatments are costly and uninsured, the executive order marks a shift toward federal acknowledgment and may pave the way for broader acceptance and scientific study.